entertainment -WSS

entertainment

author：explore 2025-09-06 01:58:46 - browse：8

DENVER — He could have been a rock star, a religious icon, the way ecstatic applause from thousands of attendees greeted the man dressed in a crisp, all-white suit as he strode onto a backlit stage. He was neither. This was Rick Doblin, the founder and evangelist of a movement to legalize psychedelic MDMA and bring the drug into mainstream medicine.

The scene in a Denver conference hall last week was a world away from the first conference Multidisciplinary Association for Psychedelic Studies (MAPS) held in 1990, when Doblin spoke alongside Timothy Leary — the ex-Harvard professor who popularized the phrase “turn on, tune in, and drop out.” That was just a few years after MDMA, also known as ecstasy, was criminalized, deemed a Schedule 1 drug “of no medical use.”

Now, as MAPS nears its goal of winning Food and Drug Administration approval for MDMA as a treatment for post-traumatic stress disorder, the perpetually smiling and energetic Doblin is basking in the adoration from both legions of “psychonauts” and unlikely yet powerful allies. “I literally love Rick Doblin,” the conservative Republican and former Texas governor Rick Perry told the audience in Denver.

It was a seemingly triumphant occasion. But even as Doblin is in sniffing distance of his lifelong quest, his once counter-cultural organization is grappling with the pressures of having to operate in the capitalist pharmaceutical sphere. MAPS was founded in 1986 as a nonprofit with deep-seated ideals. Doblin developed an “anti-patent” strategy, putting discoveries in the public domain so they couldn’t be claimed as intellectual property. He raised money to fund clinical trials of MDMA from like-minded wealthy donors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

WSS

Merck to acquire Harpoon Therapeutics for $680 million

What it's like to live with paralysis for one psychologist

The battle over 'scope creep' and who gets to be called 'doctor'

Rise in cancer among younger people worries and puzzles doctors

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

Merck to acquire Harpoon Therapeutics for $680 million

hotspot

entertainment

Wikipedia

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Cancer drug shortages should be causing more outrage

Democrats decry new health bill for going easy on private equity

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

Bright Health sells Medicare Advantage business to Molina

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Roche’s Alnylam deal shows drug firms interested in heart drugs

knowledge

Biden warns of ‘dark winter’ during final presidental debate

Rise in cancer among younger people worries and puzzles doctors

Dems pitch expanding Medicare power to negotiate drug prices

Senate panel puts off hardest PBM reforms for another day

Life science postdocs should get big pay hike, NIH panel says

The battle over 'scope creep' and who gets to be called 'doctor'

entertainment

leisure time

hotspot

entertainment